Comparing single-port and multi-port robotic surgery for rectal cancer

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This clinical trial evaluates the safety and short-term clinical efficacy of single-port robotic total mesorectal excision compared to multi-port robotic total mesorectal excision in patients with rectal cancer. It follows the IDEAL framework and focuses on various clinical outcomes, including intraoperative complications, blood loss, and postoperative recovery metrics. The study aims to determine which surgical approach offers better results in terms of complications and recovery time for patients undergoing surgery for rectal cancer.

Why it matters

Who can join: the full rules

Inclusion criteria comprised: (1) MRI-confirmed distal tumor margin \<15 cm from the anal verge, (2) biopsy-proven adenocarcinoma, (3) clinical stage I-III (AJCC 8th edition) with potential downstaging post-neoadjuvant therapy, (4) intent-to-treat with sphincter preservation and primary anastomosis, (5) documented informed consent, and (6) adult patients (≥18 years).

Where it's running

• Huichao Zheng
  Chongqing, China Recruiting

Study contacts

• Study coordinator: Huichao Zheng, MD
• Email: 625730455@qq.com
• Phone: 68757350

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• NeoCSR-Omics: CAPOX and Serplulimab Before or After Short-Course RT in Locally Advanced Rectal Cancer

  This trial tests whether giving CAPOX chemotherapy with the PD-1 blocker serplulimab before or after short-course radiotherapy helps people with locally advanced rectal cancer achieve complete clinical or pathological responses.

  Recruiting Phase 2 Chongqing University Cancer Hospital · Chongqing, Chongqing Municipality · NCT07898865

• PPISR for low- to mid-rectal cancer with anus-sparing aim

  This study tests whether Precision Partial Intersphincteric Resection can be safely used to remove certain rectal cancers while preserving the anus.

  Recruiting First Affiliated Hospital of Wenzhou Medical University · Wenzhou, Zhejiang · NCT07849023

• BT-001 plus pembrolizumab for localized pMMR rectal cancer

  This early-phase trial tests whether adding the oncolytic virus BT-001 to pembrolizumab is safe and tolerable for adults with localized pMMR rectal cancer prior to definitive surgery.

  Recruiting Phase 1 Bispebjerg Hospital · Copenhagen, Captial Region · NCT07687875

• Transanal vs Robotic Total Mesorectal Excision for Low Rectal Cancer

  This study tests whether taTME or robot-assisted TME works better for low rectal cancer patients and whether one method leads to fewer complications or conversions.

  Recruiting Sun Yat-sen University · Guangzhou, Guangdong · NCT07651553

• Single-port robotic vs traditional laparoscopic surgery for proximal stomach cancer

  This trial tests whether a single-port robotic approach can safely and effectively remove proximal stomach cancer compared with conventional laparoscopy.

  Recruiting First Affiliated Hospital of Wenzhou Medical University · Wenzhou, Zhejiang · NCT07586384

• Gynecological and sexual aftereffects following rectal cancer treatment

  This work will test whether gynecological anatomical changes after rectal cancer treatment are linked to ongoing sexual problems in women aged 18–60 who are in remission.

  Recruiting University Hospital, Rouen · Rouen · NCT07389863

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.